ArticleFrontiers in oncology2025

hNIS-based imaging to monitor treatment with the novel oncolytic virus CF33-hNIS-antiPDL1 in humans with advanced triple negative breast cancer.

Jamie Rand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.